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Stress is triggered by numerous unexpected environmental, social or pathological stimuli occurring during the life of animals,
including humans, which determine changes in all of their systems. Although acute stress is essential for survival, chronic, long-
lasting stress can be detrimental. In this review, we present data supporting the hypothesis that stress-related events are
characterized by modifications of oxidative/nitrosative pathways in the brain in response to the activation of inflammatory
mediators. Recent findings indicate a key role for nitric oxide (NO) and an excess of pro-oxidants in various brain areas as
responsible for both neuronal functional impairment and structural damage. Similarly, cyclooxygenase-2 (COX-2), another
known source of oxidants, may account for stress-induced brain damage. Interestingly, some of the COX-2-derived mediators,
such as the prostaglandin 15d-PGJ2 and its peroxisome proliferator-activated nuclear receptor PPARγ, are activated in the brain
in response to stress, constituting a possible endogenous anti-inflammatory mechanism of defense against excessive
inflammation. The stress-induced activation of both biochemical pathways depends on the activation of the N-methyl-D-
aspartate (NMDA) glutamate receptor and on the activation of the transcription factor nuclear factor kappa B (NFκB). In the case
of inducible NO synthase (iNOS), release of the cytokine TNF-α also accounts for its expression. Different pharmacological
strategies directed towards different sites in iNOS or COX-2 pathways have been shown to be neuroprotective in stress-induced
brain damage: NMDA receptor blockers, inhibitors of TNF-α activation and release, inhibitors of NFκB, specific inhibitors of iNOS
and COX-2 activities and PPARγ agonists. This article reviews recent contributions to this area addressing possible new
pharmacological targets for the treatment of stress-induced neuropsychiatric disorders.
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Introduction
The response of an organism to stress includes both
physical and behavioral adaptations, as, for example, the
“fight or flight” reaction. This response, also called
hyperarousal or the acute stress response, was first de-
scribed by Walter Cannon in 1915 (1) as the reaction to a
threat with a general discharge of the sympathetic nervous
system, priming the animal for fighting or fleeing. Some
years later, the fight or flight response was recognized as
the first stage of the general adaptation syndrome that
regulates stress responses among vertebrates and other
organisms. This syndrome was described by Selye (2) 70
years ago as a three-phase mechanism (alarm, adaptation
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and exhaustion) and was defined as the result of adapta-
tion to situations in which an organism has to fight or flight
to survive. Some of the physiological effects observed
during the first phase of alarm correspond to a fast in-
crease in catecholamines, a slow but sustained increase of
glucocorticoids in the periphery and to a very fast increase
in excitatory amino acids in many brain areas (3). These
changes are essential for surviving acute physical stress,
but they may cause adverse effects when secretion is
sustained (4). Indeed, very intense or long-lasting stress
results in a new biological equilibrium that can be either
beneficial (e.g., exercise-induced conditioning of the car-
diovascular system) or detrimental, causing damage or
disease because of a maladaptation or allostasis (5).
The stress response affects many different organs and
systems, mainly cardiovascular and central nervous system
(CNS). The response of the cardiovascular system to stress
has been ascribed mainly to catecholamine hyper-stimula-
tion and involves increased cardiac output and vascular
resistance, lipid mobilization, and stimulation of platelet ag-
gregation. When exaggerated, these effects can contribute
to the pathogenesis of hypertension, atherosclerosis, and
ischemic heart disease (6). In the CNS of rats, stress causes
reversible atrophy of hippocampal dendrites over the course
of weeks (7) and initiates apoptotic changes in cortical and
hippocampal areas (8). Furthermore, exposure to chronic
unpredictable stress can cause permanent loss of neurons
in rodents (7) and potentiated lipopolysaccharide (LPS)-
induced nuclear factor kappa B (NFκB) activation and mRNA
expression of pro-inflammatory genes in the frontal cortex
and hippocampus (9). In humans, atrophy of the hippocam-
pus has been observed. It was first described in war-related
post-traumatic stress disorder and major depression, coex-
isting with a decrease in neuronal activity (10). This atrophy,
which also affects other areas (temporal lobe, orbitofrontal
cortex) and whole brain volume, coexists with decreased
blood flow and metabolism in prefrontal cortex of patients
suffering depression (10).
Although stress is not a disease by itself, continuous
exposure to stressful stimuli has been directly related to the
onset, progression or outcome of many pathological pro-
cesses. Some of the detrimental actions of stress hormones
in the brain may be mediated via the release of secondary
mediators. We will review the evidence on brain oxidative
and nitrosative mediators in stress-induced injury and the
basis for a possible pharmacological intervention.
Physiology of stress
The hypothalamus-pituitary-adrenal axis
The activation of mechanisms in response to stress is
coordinated by the hypothalamus-pituitary-adrenal (HPA)
axis. Although the pathways through which the brain trans-
lates the stressor nature of a particular stimulus into the
integrated response at the hypothalamus are not known,
neural inputs from catecholaminergic, serotonergic and
cholinergic brain nuclei have been involved (11).
The parvocellular neurons of the paraventricular nucle-
us in the hypothalamus express corticotrophin-releasing
factor. After experiencing a stress stimulus, the cells in the
paraventricular nucleus secrete corticotrophin-releasing
hormone. Once there, this substance acts on the anterior
pituitary stimulating the proopiomelanocortin-producing
cells to release adrenocorticotrophin. Adrenocorticotro-
phin is then released into the systemic circulation and
transported to the adrenal cortical receptors where it in-
duces the production of catecholamines and glucocorti-
coids. The detection of increased levels of these sub-
stances as well as sustained elevated levels of glucocorti-
coids in plasma is a typical feature of the stress response.
Glucocorticoids
Glucocorticoids are considered to be anti-inflamma-
tory, immunosuppressive and immunomodulatory under
normal conditions. The mechanisms underlying these ef-
fects of glucocorticoids in the periphery are well under-
stood and include inhibition of lymphocyte proliferation
and dendritic cell maturation, and apoptosis of basophils,
eosinophils and T-cells (12). However, in recent years, the
classic view that glucocorticoids are universally anti-in-
flammatory has been challenged at a variety of levels,
mainly in the CNS. Indeed, in the brain, glucocorticoids are
not uniformly anti-inflammatory, and can even be pro-
inflammatory at the level of cell extravasation and migra-
tion as well as inflammatory messenger, and transcription
factor levels (12).
Chronic and sustained release of glucocorticoids par-
ticipates in the atrophy observed in certain brain areas
after intense and long-lasting stressing situations (4). In
fact, similar alterations are detected in patients suffering
Cushing’s syndrome, who have a chronic hyper-produc-
tion of glucocorticoids. The excess of glucocorticoids dam-
ages the hippocampus and this can contribute to an even
larger increase in the production of glucocorticoids be-
cause the feedback mechanism exerted by them on the
HPA axis is inhibited (10).
One of the mechanisms proposed for this neurodegen-
eration due to glucocorticoid hyper-secretion is the inhibi-
tion of glucose transport in brain neurons and glia, which
could be the result of the redirection of the energy towards
the muscles in order to facilitate the escape from the
stressor. These effects seem to be mediated by the GR
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(type II receptor of glucocorticoids) and are due to a
translocation of the glucose transporter molecules from
the cellular surface to inside the cell as well as a reduction
in the levels of the glucose transporter mRNA (7).
Glucocorticoids also promote a reduction of ATP levels
during neurological insults (7), an effect which has also
been observed in brain cortex from rats exposed to stress
(13).
Another important mechanism for glucocorticoids or
stress-induced brain damage is their effects on excitatory
amino acids. When neurological survival is threatened by
the release of large quantities of glutamate, glucocorti-
coids worsen this situation increasing calcium mobilization
inside the cells, as well as interfering with glutamate reup-
take. These effects reflect both direct and indirect conse-
quences of glucocorticoids: by altering profiles of subunits
of calcium channels or by inhibiting Ca2+ ATPase (re-
viewed in Ref. 7). Glucocorticoids also worsen degenera-
tive events downstream of the Ca2+ excess (cytoskeletal
proteolysis, microtubule abnormalities and accumulation
of reactive oxygen specie). This final point is particularly
interesting, giving the increasing emphasis on the role of
reactive oxygen species in neuronal injury, which is de-
tailed below.
Mechanisms by which stress induces
oxidative/nitrosative damage in the brain
Release of excitatory amino acids
It is well known that one of the main effects of the stress
response is the release of large quantities of excitatory
amino acids, such as aspartate and glutamate, in different
brain areas, an effect occurring rapidly after the onset of
stress (20 min to 2 h) (3).
Released glutamate can bind to different receptors; the
main one being the N-methyl-D-aspartate (NMDA) sub-
type, whose activation causes the mobilization of free
cytosolic calcium. Excess in the intracellular calcium con-
centration over-activates certain calcium-dependent en-
zymes resulting in the generation of oxygen radicals, pro-
tein misfolding and cytoskeletal damage (14), constituting
the process known as excitotoxicity.
Glucocorticoids potentiate the damaging effect of cal-
cium not only by inducing its influx to the cytosol but also by
inhibiting its efflux via the Ca2+/ATPase and the Ca2+/Na+
exchanger (7). The relationship between the glucocorti-
coid-mediated effects on glutamate and the consequent
neuronal alterations has also been observed in experi-
mental models of stress (15).
The increase in the extracellular concentration of gluta-
mate can be achieved not only by releasing larger quanti-
ties of this amino acid but also by a reduction in its clear-
ance. If the clearance of glutamate is not sufficient to avoid
the over-stimulation of its receptors, subsequent cellular
damage can be promoted (16). Both neurons and astroglia
are capable of transporting glutamate by a high-affinity,
sodium-dependent transport. To date, high-affinity, so-
dium-dependent glutamate transporters have been cloned
from rodent and human tissue, known as excitatory amino
acid transporters (EAAT) 1 to 5 (17). Immunohistochemi-
cal studies have revealed that EAAT1 and EAAT2 are
present primarily in astrocytes, while EAAT3 and EAAT4
are distributed in neuronal membranes, and EAAT5 is
retinal.
The involvement of transporter regulation and its modi-
fication by stress can be evaluated by studying synaptoso-
mal glutamate uptake and expression of the main trans-
porters EAAT1, EAAT2 and EAAT3 after different experi-
mental stress protocols. Indeed, stress causes a decrease
in synaptosomal glutamate uptake, indicating a dysfunc-
tion of glutamate transporters at this level (18). Further-
more, glutamate transporter (EAAT2 and EAAT3) expres-
sion in brain cortical membranes is decreased after stress,
possibly explaining the increase in basal serum glutamate
release detected in stressed animals (19).
This poses the question what mechanism is responsi-
ble for the increased glutamate release after stress? In
certain situations such as ischemia, the transport systems
responsible to maintain low extracellular glutamate levels
can be reversed causing the opposite effect due to the fall
in ATP production, i.e., increased release. This fall in ATP
has also been observed in the brain of stressed animals
mediating, at least in part, the subsequent reversal of the
glutamate uptake systems and increasing the release of
glutamate (20).
Release of cytokines in the brain during stress
Although a considerable amount of evidence has shown
that physical and psychological stress elevates plasma
levels of several cytokines (i.e., tumor necrosis factor α,
TNF-α; interleukin-1, IL-1) in animals and humans sub-
jected to psychological stress, anxiety states and anorexia
nervosa, the physiological significance of this elevation is
not known (21). Although most cytokines present in the
brain after stress come from the periphery, there are impor-
tant cellular sources of these mediators throughout the
brain, mainly endothelial cells and epithelial cells of the
choroid plexus and ventricles as well as glia and neurons
from dentate gyrus of the hippocampus and the anterior
pituitary, anterior olfactory nucleus, thalamus, hypothala-
mus, amygdala, and cerebellum (reviewed in Ref. 22).
One of these cytokines, TNF-α, is rapidly produced in
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Activation of transcription factors during stress: NFκB
NFκB is a transcription factor widely expressed in the
CNS. It consists of homodimers or heterodimers of a family
of structurally related proteins. The most commonly found
type is the heterodimer composed of a p65 (RelA) and a
p50 subunit. This dimer can also bind to a third protein
called IκB, which inactivates NFκB. The activation of this
transcription factor comprises the sequential activation of
different enzyme complexes such as NFκB-induced ki-
nase (NIK), which, in turn, activates IκB kinase (IKK) that
catalyzes the phosphorylation of two serines in NFκB. This
constitutes the signal for the degradation of IκB. Once free
of the inhibitory subunit, NFκB can enter the nucleus
where it binds to specific κB DNA consensus sequences in
the enhancer region of a variety of κB-responsive genes,
some of which are involved in oxidative-nitrosative dam-
age (29).
Stress activates NFκB in brain cells as soon as 4 h after
the onset of stress in rats (reviewed in Ref. 19) and
potentiates the activity of this transcription factor in the
frontal cortex and hippocampus of rats under endotoxic
shock (induced by LPS) (9). This activation of NFκB after
stress was confirmed in experiments with humans and
transgenic mice subjected to psychological or immobiliza-
tion stress (30).
Many stimuli such as viral and bacterial infection, gluta-
mate, UV light, ionizing radiation, free radicals, and cyto-
kines activate NFκB (29). One of these activators is TNF-
α (31). The implication of TACE and TNF-α in stress-
induced activation of NFκB was confirmed after finding
that the pharmacological inhibition of TACE also blocked
the stress-induced activation of NFκB (27).
Additionally, the essential role of NMDA activation as a
trigger factor in this process is of particular interest, since
blockade of this receptor decreases NFκB translocation
induced by LPS (9), and also decreases stress-induced
TACE activation and TNF-α release (19).
We will now examine the consequences of the activa-
tion of such a transcription factor, leading to the expression
of several responsive genes such as those involved in
oxidative/nitrosative products.
NFκB-related oxidative/nitrosative products in stress
Some of the genes responsive to NFκB are oxidative/
nitrosative sources. These include inducible nitric oxide
synthase (iNOS, NOS-2) and cyclooxygenase-2 (COX-2).
iNOS. Nitric oxide (NO) is synthesized from L-arginine
by the enzymes NO synthases: endothelial, neuronal and
an isoform expressed during inflammatory reactions (iNOS).
iNOS is an enzyme expressed after exposure of cells to
several noxious agents such as cytokines or LPS (32).
the brain in response to tissue injury. TNF is a group of
cytokines that consists of two forms, namely the α and β
forms, which are the products of two different genes. Many
studies have been focused on the α form because its
excessive production can cause tissue damage (23). TNF-
α levels are increased in the CNS after damage due to
traumatic injury, ischemia, infections, or diseases that
involve brain degeneration, playing an important role in the
adaptive response to these conditions.
TNF-α is released in its soluble form from its mem-
brane-bound precursor by a membrane-anchored zinc
metalloproteinase, identified as a disintegrin and metallo-
proteinase (ADAM) called TNF-α convertase (TACE/
ADAM17) (24). TACE cleaves pro-TNF-α at the cell sur-
face releasing the mature form from the cell membrane.
Like other cytokines, TNF-α exerts its effects by binding
first to specific surface receptors on target cells. There are
two types of TNF receptors: the p55 and the p75 also called
TNFR-1 and –2, respectively (25).
Either TACE expression or activity has been found to
change in some neuroinflammatory conditions in which an
increase in TNF-α levels has been described, such as
stroke, multiple sclerosis or traumatic injury (26). We have
shown that after exposures to only 30 min of restraint
stress TACE enzymatic activity in the brain cortex is in-
creased (27). The predictable consequence of TACE acti-
vation is a larger release of TNF-α. In fact, this has been
found in brain cortex samples obtained from stressed rats.
While the activity of TACE was increased after half an hour
of immobilization, the levels of soluble TNF-α were in-
creased one hour after the onset of stress. The implication
of TACE in this process was demonstrated by the reduc-
tion in the TNF-α levels in stressed animals treated with the
preferred inhibitor of TACE activity BB1101 (27). TNF-α
has been identified also as a main regulator of persistence
of the oxidative changes after sustained, inescapable and
predictable stress (28).
Trying to go further in the sequence of events initiated
by stress exposure, we also investigated the possible
influence of glutamate in the release of TNF-α by blocking
the NMDA glutamate receptor with the specific non-com-
petitive compound MK-801 (dizocilpine). Interestingly,
NMDA blockade not only decreases stress-induced activ-
ity and expression of TACE, but also its constitutive ex-
pression, as well as TNF-α levels (27). Taken together,
these results demonstrate a crucial role for glutamate in
the initiation of a response that shares certain features with
the inflammatory processes. These results highlight a di-
rect central regulatory effect of stress-induced neuroin-
flammation to be added to the entry of cytokines from
outside the brain.
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This NOS isoenzyme mediates cytotoxicity in many cell
systems, mainly because of the oxidative/nitrosative ef-
fects produced by extensive and prolonged release of NO,
which finally lead to a production of other oxidant species
such as peroxynitrite (33).
Evidence has been presented for the role of NO in
some pathological processes in the CNS. Indeed, the
excessive generation of NO has been demonstrated in
epilepsy, hypoxic-ischemic damage and neurodegenera-
tive disorders including Alzheimer’s and Parkinson’s dis-
eases and Huntington’s corea (32).
It has been reported that exposure to stress results in
increased NO production in the brain and periphery. A
similar transient stimulation of NO release also occurs in
plasma of humans subjected to stress (reviewed in Ref.
19). This systemic release of NO may offset the vasocon-
strictor and pro-aggregatory effects of stress hormones
and mediators during the first stages of the stress re-
sponse.
Immobilization stress increases brain iNOS activity
and expression as soon as 6 h after the onset of stress
(34), and longer periods of stress produce higher levels of
iNOS expression and activity (reviewed in Ref. 19). The
detrimental effects of the long-term stress induction of
iNOS include accumulation of membrane aldehyde prod-
ucts (peroxidation products), disruption of blood brain bar-
rier and mitochondrial impairment (19). Pharmacological
data obtained using specific inhibitors of iNOS support the
conclusion of the participation of iNOS in stress-induced
damage. It is unclear whether NO per se is the effector
molecule of neuronal damage. A persistent elevation of
NO levels can result in generation of a potent oxidant,
peroxynitrite (ONOO-) from superoxide and NO. Peroxyni-
trite is a tissue-damaging agent that acts by the initiation of
lipid peroxidation, oxidation of sulfhydryl groups and
nitrosation of tyrosine-containing molecules. The huge
accumulation of NO and over-expression of iNOS ob-
served in the brain during chronic stress probably leads to
the production of reactive oxygen or nitrogen species such
as peroxynitrite (19).
iNOS induction in stress depends on NFκB activation.
This was supported by the use of an inhibitor of NFκB
activation such as pyrrolidine dithiocarbamate, which de-
creased the activity and expression of iNOS in stressed
animals (34).
Pharmacological experiments were carried out to study
the possibility that cytokines and excitatory amino acids
account for the stress-induced activation of iNOS. Indeed,
specific blockers of the NMDA receptor of glutamate (MK-
801) or TACE inhibitors (BB1101) partially inhibit the stress-
induced iNOS expression and activation (25).
COX-2. As is the case for NOS, there are different
isoforms of COX, namely COX-1, -2 and -3. COX-1 is
constitutively expressed in almost all tissues. COX-2 is
induced and expressed by cells that are involved in inflam-
mation (e.g., macrophages, monocytes, synoviocytes) and
is responsible for the synthesis of prostanoids involved in
pathological processes (31). COX-3 has been recently
discovered as an RNA splicing variant of COX-1.
COX-2 is one of the most important components of the
inflammatory response, and its reaction products are re-
sponsible for cytotoxicity in models of inflammation. Al-
though COX-2 is expressed constitutively in brain cells, its
expression is up-regulated in several neurological dis-
eases, such as stroke, Alzheimer’s dementia and seizures
(35).
The mechanisms by which COX-2 produces cell dam-
age involve the biosynthesis of prostaglandins, which gen-
erates free oxygen radicals that can result in injury. On the
other hand, prostaglandin itself also can be responsible for
the damage by inducing glutamate release from astrocytes
or apoptosis (reviewed in Ref. 36).
The link between the action of COX-2 and neurological
damage is deduced from numerous studies in which inhibi-
tion of induced COX-2 activity (37) or deletion of its gene
(38) result in neuroprotection.
Studies have shown an increase in COX-2 mRNA
levels due to forced swim stress in mice (39). Recently, an
increased expression and activity of COX-2 in brain cortex
has been observed after a short exposure (4-6 h) to re-
straint stress in rats (19). Interestingly, specific pharmaco-
logical tools that inhibit COX-2 activity (NS-398) prevent
the increase on membrane lipid peroxidation mediators
and the depletion of the main tissular antioxidant (glutathi-
one), suggesting that this COX isoform is involved in the
accumulation of oxidative mediators found in the brain
after stress. The activity and expression of COX-2, as in
the case of iNOS, is mediated by glutamate and NFκB (19).
A COX-2-dependent mechanism of
inflammatory balance: deoxy-prostaglandins
and PPARS
All organisms have complex defense mechanisms that
allow them to adapt to and survive stress. Two antiinflam-
matory mechanisms have received great interest in the
literature during the last years: one is the counterbalancing
vagal reflex after sepsis, hemorrhagic shock, ischemia
and other inflammatory syndromes, which inhibits cytokine
release and thereby prevents tissue injury and death (re-
viewed in Ref. 40), and the other is carried out by certain
cyclopentenone prostaglandins derived from the differen-
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tial activation of COX isoforms by different physio-patho-
logical stimuli. This latter mechanism is beginning to be
considered as a possible local endogenous regulator of
the inflammatory response in neurodegenerative condi-
tions and has received considerable attention from the
stress scientists.
The most studied anti-inflammatory prostaglandin is
the prostaglandin 15-deoxy-prostaglandin (15d-PGJ2), a
structural, non-enzymatic derivative from the prostaglan-
din D2. This prostaglandin is the endogenous ligand pro-
posed for the gamma isoform of the subfamily of peroxi-
some proliferator-activated nuclear receptors, PPARγ.
These receptors have been thought to be directly involved
in the regulation of the inflammatory response in several
animal models of neuropathologies having a clear associ-
ated inflammatory component (41). PPARγ also possesses
a great number of synthetic ligands such as the family of
anti-diabetic drugs known as thiazolidinediones (TZDs),
which include rosiglitazone, troglitazone, pioglitazone, and
ciglitazone (42).
Kainu et al. (43) carried out the first study demonstrat-
ing the presence of PPARγ mRNA and protein in CNS
cells. Later, other more detailed studies have demon-
strated that PPARγ presents a high degree of expression in
the rat cerebral frontal cortex, in all layers and mainly in the
neurons of layer II, showing immunostaining in the nuclear
and cytoplasmic compartments (44). Also, PPARγ expres-
sion has been detected in microglial cells and in astro-
cytes, making these cells potential targets for the PPARγ
ligand anti-inflammatory activity in neurological diseases
having an associated inflammatory component (45).
PPARγ and its ligands are master regulators of cere-
bral physiology and potential therapeutic targets for the
treatment of several pathological conditions within the
CNS. A large number of animal models of neuropatholo-
gies (ischemia, Alzheimer’s disease, multiple sclerosis,
Parkinson’s disease) have been used to study the effects
of treatments with PPARγ agonists (41). In addition, some
studies already indicate the utility of these compounds to
treat certain gliomas and astrocytomas and to control
lymphocyte T proliferation (41). Currently, all this evidence
from basic research has reached the clinical level: clinical
trials are being carried out to determine the effectiveness
and safety of the treatment with PPARγ agonists in Alzhei-
mer’s disease and cerebral ischemia (46). At the moment,
the results are promising. Also, trials on progressive sec-
ondary multiple sclerosis have shown positive results.
Treatments with PPARγ agonists have been demonstrated
to be effective also in neuroinflammation models in in vivo
studies of neuropathologies such as Alzheimer’s disease,
multiple sclerosis and Parkinson’s disease (47).
This promising anti-inflammatory pathway is also
strongly related to stress exposure. In fact, studies from
our laboratory have shown that acute immobilization stress
enhances both the production of 15d-PGJ2 and the ex-
pression of PPARγ in the cortex of the rat brain, as demon-
strated by Western blot and immunohistochemical analy-
ses. The staining was particularly evident in layers II to VI
of the cortex of stressed animals, in neurons and astro-
cytes (48).
We have also demonstrated that both synthetic and
natural PPARγ ligands prevent the inflammatory and oxi-
dative/nitrosative consequences of stress exposure in the
CNS of rats subjected to immobilization stress (49). The
mechanisms by which these compounds prevent these
effects include inhibition of stress (acute and chronic)-
induced increase in iNOS activity, NFκB blockade (by
preventing stress-induced IkBα decrease) and inhibition of
TNF-α release in stressed animals. Other research has
indicated the capacity of the PPARγ agonists (TZDs and
15d-PGJ2) to reduce the expression of the pro-inflamma-
tory cytokine TNF-α and iNOS, gelatinase B (MMP-9) and
COX-2 in LPS-stimulated macrophages in glial cells and
neurons. These proteins contribute to the inflammatory
damage observed in certain neurological diseases (47).
PPARγ agonists may also activate antioxidant pathways
such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
(50).
The neuroprotection afforded by treatment with PPARγ
agonists is extended to sub-acute restraint stress para-
digms (7 or 14 consecutive days). In this way, treatment
with PPARγ agonists exerts direct protective action on the
cerebral glucose and glutamate metabolism disrupted af-
ter stress exposure (regulating the expression of the neu-
ronal glucose transporter GLUT-3 and the predominant
glial glutamate transporter EAAT-2), mechanisms to add
to its above-discussed anti-inflammatory/antioxidant ef-
fects, adding new therapeutic implications to the manage-
ment of patients at risk of stressful events (51).
All of these findings clearly support the view that immo-
bilization stress activates PPARγ in the brain, and pharma-
cological manipulation of intrinsic pathways such as PPARγ
could provide protection in neuroinflammatory conditions.
A question of further interest is the possibility that this
pathway serves as a mediator of “central neurogenic neu-
roprotection” or “adaptive plasticity”, as proposed in the
stressed brain. It has been recently demonstrated that this
pathway is finely regulated in the brain by stress hor-
mones, including catecholamines, glucocorticoids and
excitatory amino acids (52).
The possible use of exogenously administered PGJ2
as a tool to maintain antiinflammatory balance in this
1043
Braz J Med Biol Res 41(12) 2008
Neuroinflammation and stress
www.bjournal.com.br
condition deserves special attention. In fact, expression of
COX-2 can be up- or down-regulated in situations of neu-
roinflammation. In basal conditions (inactivated stage),
physiological PGD2 metabolites such as PGJ2 closes a
negative feedback loop on COX-2 expression, whereas in
activated stages, such as stress, COX-2 is activated by
enhanced levels of PGD2 metabolites, with production of
its main product, PGE2. By administering supraphysiologi-
cal doses of PGJ2, as we do in stress, one could expect an
inhibition in COX-2 expression and PGE2 production, as
seen in different models (53). Accordingly, exogenous
administration of PGJ2 should exert a more powerful anti-
inflammatory effect, as it occurs in the case of the anti-
pyretic effect of this endogenous ligand. Thus, the antiin-
flammatory effect of PGJ2 is more apparent in stressful
situations than in resting status, due to induction of endog-
enous PGJ2 production, which, when combined with exog-
enous 15d-PGJ2, could exert a more powerful effect (53).
These observations support the rationale of using supra-
physiological doses of PGJ2.
Stress, aging and neurodegenerative diseases
Stress, inflammation and NO have been shown to be
involved in neurodegeneration. In fact, stress causes defi-
cits especially in spatial memory performance, and this
effect may be important for pathophysiological processes
connected with aging, as well as degenerative diseases
such as Alzheimer’s and Parkinson’s diseases (54). In
addition, hippocampal atrophy may be involved and the
stress-related activation of the CNS and/or HPA axis could
represent a pathophysiological starting point (7). More-
over, the aging hippocampus apparently is more suscep-
tible to stress, and this vulnerability may be increased in
Alzheimer’s disease (55). Stress has been demonstrated
to be part of mechanisms related to anxiety and depres-
sion. NO may also be involved in the pathophysiology of
anxiety/depression, since it interferes with various compo-
nents and underlying mechanisms of the stress response
(55). Studies performed on an animal model for chronic
mild stress (a situation that mimics human depression)
showed that the hippocampal atrophy of neurons present
in these rats was inhibited by fluoxetine, an antidepressant
that is capable of blocking NO production (56). Also, a
recent study showed that the cytokine IL-1α is a critical
mediator of the antineurogenic and depressive-like behav-
ior caused by acute and chronic stress and this effect is
mediated by the NFκB signaling pathway (57).
Energy deficiency and dysfunction of Na,K-ATPase
are common consequences of many pathological insults
and stress. Glutamate through cyclic guanosine mono-
phosphate (GMP) and cyclic GMP-dependent protein ki-
nase (PKG) has been shown to stimulate α2/3-Na,K-ATPase
activity in the CNS (58). Thus, a slight impairment of this
pathway may amplify the disruption of ion homeostasis in
the presence of a non-lethal insult. Studies in rats suggest
that basal age-related decline in sodium pump activity is a
consequence of changes in different steps of the cyclic
GMP-PKG pathway. On the other hand, age-related re-
duction in glutamate-positive modulation of cerebellar α2/3-
Na,K-ATPase is linked to a defective PKG signaling path-
way (59). The loss of the ability of α2/3-Na,K-ATPase to
respond to glutamate through a cyclic GMP-PKG cascade
could be a failure in an important mechanism for rectifying
ionic disturbances that may be present in aging processes
and may predispose to or potentiate an effect of stress in
the manifestation of age-related degenerative disorders.
In fact, chronic predictable and unpredictable stress de-
crease the neuronal Na,K-ATPase activity and high levels
of glucocorticoid have been detected in 24-month-old rats
(Munhoz CD, Scavone C, unpublished results), which
could induce a further reduction of ATP levels during a
neurological insult. It is interesting to note that the aging
process (30-month-old animals) induces up-regulation in
constitutive NFκB binding activity in the frontal cortex,
which in the presence of glucocorticoid levels could poten-
tiate LPS-induced NFκB activation and an increase in
mRNA of proinflammatory genes (9). In addition, rats with
increased HPA reactivity induced by prenatal stress or by
the absence of neonatal handling show an early decline of
cognitive functions associated with the hippocampus, as
well as increased propensity to self-administer drugs such
as amphetamine and cocaine (55). In addition, exposure to
both chronic restraint and unpredictable stress increased
cocaine-induced locomotion and basal corticosterone plas-
ma levels and chronic unpredictable stress also displayed
the largest locomotor response following a challenge dose
with cocaine compared with control and chronic restraint
stress groups (60). Drug abuse is associated with changes
in brain function and neurodegenerative processes, which,
for some drugs, have been shown to be associated with
the induction of apoptotic/necrotic cell death (Lepsch LB,
Munhoz CD, Kawamoto EM, Lima LS, Scavone C, unpub-
lished results). Thus, life-long patterns of HPA function are
probably important to determine the susceptibility of the
body to stress or insults during the aging process.
Future directions
The impact of stressor exposure on brain function has
been widely investigated in the last years and is a main
concern of current neuropsychiatry. Furthermore, the num-
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ber of reports indicating that long-lasting stress affects
synaptic plasticity, dendritic morphology and neurogen-
esis in animals and induces both clinical and anatomical
features of neurotoxic damage in humans (i.e., post-trau-
matic stress disorder) is increasing. The vulnerability of
many systems of the body to stress in aging is therefore
influenced by experiences during life and is probably linked
to the reactivity of the HPA axis. The main clinical corre-
lates of stress-related neuropsychiatric disorders are de-
pressive disorders, which are among the most common
neuropsychiatric illnesses and represent a significant pub-
lic health problem. The precise molecular and cellular
events induced by stress and responsible for the brain
damage found in this condition are still a matter of debate,
but recent investigations point out a role for oxidative-
nitrosative mediators.
The high-output isoform of iNOS (NOS-2) has been
implicated in cellular toxicity in many cell systems includ-
ing brain. In this context, it has been demonstrated that
stress induces the expression of iNOS in rat brain and that
its inhibition protects against stress-induced cell damage
in this model. Once iNOS is expressed, the formation of
large amounts of oxygen and nitrogen reactive species
may account for the oxidation of cellular components found
after stress in the rat brain. A plausible consequence of this
is the volume reduction that has been described in several
brain structures in chronically depressed patients and
other stress-related disorders.
On the other hand, the COX pathway has also been
implicated in stress-induced brain damage. COX-2 is in-
duced in stress and has been involved in the damage
associated with this condition. According to its condition of
inducible enzyme, and similarly to iNOS, the promoter of
the immediate-early gene COX-2 depends on the activa-
tion of NFκB in stress. Both enzymatic sources of oxidative
mediators in the brain depend on the activation of the
NMDA type of glutamate receptor, and, in the case of
iNOS, its activation also depends on the release of TNF-α.
The findings reviewed here indicate that excitatory
amino acids and subsequent activation of NFκB account
for stress-induced iNOS and COX-2 expression and activ-
ity in the cerebral cortex (Figure 1). They support a pos-
sible neuroprotective role for specific inhibitors in this
situation. The usefulness of PPAR agonists and PGJ2 as a
tool for down-regulation of brain inflammation is an impor-
tant area to be developed in the future.
Figure 1. Stress-induced oxidative/nitrosative mediators in the
brain. TACE = TNF-α convertase; NFκB = nuclear factor kappa
B; TNF-α = tumor necrosis factor alpha; iNOS = inducible nitric
oxide synthase; COX-2 = cyclooxygenase-2; PGJ2 = prosta-
glandin 15d-PGJ2; PPARγ = peroxisome proliferator-activated
nuclear receptor gamma; BBB = blood-brain barrier. *Possible
targets for drugs. Straight line = increase; dotted line = decrease.
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